Seegene, Inc.

KOSDAQ 096530.KQ

Seegene, Inc. Price to Sales Ratio (P/S) on January 14, 2025: 2.80

Seegene, Inc. Price to Sales Ratio (P/S) is 2.80 on January 14, 2025, a -1.44% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Seegene, Inc. 52-week high Price to Sales Ratio (P/S) is 4.21 on August 19, 2024, which is 50.46% above the current Price to Sales Ratio (P/S).
Seegene, Inc. 52-week low Price to Sales Ratio (P/S) is 2.35 on June 27, 2024, which is -16.02% below the current Price to Sales Ratio (P/S).
Seegene, Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 2.81.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

KOSDAQ: 096530.KQ

Seegene, Inc.

CEO	Dr. Jong-Yoon Chun
IPO Date	Sept. 10, 2010
Location	South Korea
Headquarters	Taewon Building
Employees	63
Sector	Health Care
Industries Pharmaceuticals Biotechnology Medical Instruments

Description

Seegene, Inc. manufactures and sells molecular diagnostics products worldwide. It offers IVD products comprising respiratory disease detection products for respiratory infections; gastrointestinal disease detection products for gastrointestinal tract infections; human papillomavirus detection products; sexually transmitted infections causative pathogens detection products; tuberculosis detection products; drug resistance products; Magicplex sepsis real-time test for the detection and identification of sepsis causing pathogens; and meningitis detection products. The company also provides other products for the detection of six SNPs in factor II, factor V, and MTHFR genes; BRAF mutation characteristic for papillary thyroid carcinoma from samples of thyroid tissue, fine needle aspiration biopsy, H&E slides, and paraffin-embedded tissues; Apolipoprotein E genotypes; and BCR/ABL fusion gene from blood and whole bone marrow. In addition, it offers PCR machines; vial cap management systems; nucleic acid extraction systems; automated liquid handling workstations from nucleic acid extraction to PCR setup; and real-time PCR detection systems. Seegene, Inc. was founded in 2000 and is headquartered in Seoul, South Korea.

Key trends

Past 5 years